In the post-pandemic climate, there has been a sort of “forced evolution” for marketers within the life sciences sector. There is renewed focus on being able to effectively reach various audience segments, whether it is potential patient populations, HCPs, caregivers, or payers. The overall goal should move to being able to gain a much stronger level of engagement and get to a segment of one.

One of the latest initiatives being spearheaded by EMA is publishing ePI, or electronic product information. In some respects, the pharma industry has lagged behind other major industries in terms of how documentation and critical information is relayed to the end patient. Due to regulations, pharma still heavily relies on traditional Microsoft Word-based documentation for labeling that is managed with track changes and then ultimately printed. Besides not leveraging the latest technologies for patient benefit, the current process makes for a cumbersome translation process to provide the PI in the required 25 languages. The introduction of ePI will facilitate more effective and faster change management, version control, translation, and use of advanced translation tools. 

Centralizing global content for the migration of clinical outcome assessments to electronic format can streamline and simplify patient data reporting.

Pharma digital marketing: check out some of the ways omnichannel and below-the-line marketing can improve customer experience and engagement.

A key concern for pharma companies is keeping a close eye on publications that might mention their product and its potential impact on the public. These publications can be extremely dense in volume, commanding careful review of multiple documents across several different sources. This review often needs to take place in a relatively short timeline and with strict reporting requirements.

Rethink product development using patient engagement strategies to help improve patients’ health and well-being. Read about challenges and opportunities.

The ACC last month hosted the San Francisco Bay Area Life Sciences CLE Conference, giving TransPerfect Legal Solutions (TLS) team members the opportunity to learn and connect with colleagues. One of the panels, moderated by Alex Trimble, Partner at Mintz Levin, Cohn, Ferris, Glovsky, and Popeo, focused on prioritizing patent filings. Panelists included Briana Barron, Arcus Biosciences Vice President of Intellectual Property, Alok Goel, Cepheid Senior IP Counsel, and Wesley Jackson, Valitor CEO. Eric Elting, TLS Regional Director, attended the panel discussion and came away with some valuable insights.

Digital health plays a vital role in improving patient engagement. Learn about some important considerations for introducing these innovations globally.

For medical affairs teams to achieve digital excellence, omnichannel delivery of medical information using a CCMS is critical. Here’s how a CCMS can be beneficial.

AI in pharmacovigilance (PV) provides many opportunities for PV teams in areas such as case intake, local literature monitoring, case processing, and more.

Earlier this month, the ACC hosted an illuminating panel presentation on Life Sciences Litigation: A Look at Milestone Disputes & Recent Trends. Panelists included Lauri Mims and Jennifer Huber, both Partners at Keker Van Nest & Peters, and Ann Byers, Director, Shareholder Advisory at SRS Acquiom.

TransPerfect Legal Solutions (TLS) Regional Director Eric Elting attended the panel discussion and came away with some valuable insights.

Learn why life sciences and healthcare companies are investing in ever-evolving AI translation technology such as machine translation and translation memory.